{"title":"Adeno-Associated Viruses (AAVs)","description":"\u003cp\u003e\u003cspan\u003eDiscover our exceptional selection of Adeno-Associated Viruses (AAVs), meticulously crafted to meet the specific needs of research labs. Our AAVs offer unparalleled reliability and precision, enabling seamless gene delivery for a multitude of applications including gene therapy and neuroscience research. With a legacy of quality and innovation, our AAVs guarantee consistent and reproducible results, elevating your scientific pursuits. Explore our comprehensive catalog to find the perfect AAV solution for your projects and open the door to groundbreaking possibilities in genetic research and experimentation.\u003c\/span\u003e\u003c\/p\u003e","products":[{"product_id":"aav-null-aav-serotype-1-bhv21500001","title":"AAV-Null (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Null\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500001\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eThe null (empty) transgene contains no functional payload, making this vector ideal as a matched delivery and promoter control.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020164915565,"sku":"SL100802-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020164948333,"sku":"SL100802-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500001_aav-null-aav-serotype-1_SL100802.jpg?v=1770796172"},{"product_id":"aav-gfp-aav-serotype-1-bhv21500002","title":"AAV-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500002\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020164981101,"sku":"SL100803-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165013869,"sku":"SL100803-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500002_aav-gfp-aav-serotype-1_SL100803.png?v=1770796172"},{"product_id":"scaav-gfp-aav-serotype-1-self-complementary-bhv21500003","title":"scAAV-GFP (AAV Serotype 1, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500003\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165046637,"sku":"SL100803-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165079405,"sku":"SL100803-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500003_scaav-gfp-aav-serotype-1-self-complementary_SL100803-SC.png?v=1770796172"},{"product_id":"aav-cre-aav-serotype-1-bhv21500004","title":"AAV-Cre (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500004\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165112173,"sku":"SL100804-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165144941,"sku":"SL100804-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500004_aav-cre-aav-serotype-1_SL100804.png?v=1770796172"},{"product_id":"scaav-cre-aav-serotype-1-self-complementary-bhv21500005","title":"scAAV-Cre (AAV Serotype 1, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500005\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165177709,"sku":"SL100804-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165210477,"sku":"SL100804-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500005_scaav-cre-aav-serotype-1-self-complementary_SL100804-SC.png?v=1770796173"},{"product_id":"aav-cre-gfp-aav-serotype-1-bhv21500006","title":"AAV-Cre-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500006\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/1).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165243245,"sku":"SL100805-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165276013,"sku":"SL100805-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500006_aav-cre-gfp-aav-serotype-1_SL100805.png?v=1770796173"},{"product_id":"aav-u6-shrna-scramble-gfp-aav-serotype-1-bhv21500007","title":"AAV-U6-shRNA(Scramble)-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(Scramble)-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500007\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165308781,"sku":"SL100806-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165341549,"sku":"SL100806-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500007_aav-u6-shrna-scramble-gfp-aav-serotype-1_SL100806.png?v=1770796174"},{"product_id":"aav-cag-gfp-aav-serotype-1-bhv21500008","title":"AAV-CAG-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500008\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165374317,"sku":"SL100807-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165407085,"sku":"SL100807-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500008_aav-cag-gfp-aav-serotype-1_SL100807.png?v=1770796174"},{"product_id":"aav-synapsin-gfp-aav-serotype-1-bhv21500009","title":"AAV-Synapsin-GFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500009\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165439853,"sku":"SL100808-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165472621,"sku":"SL100808-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500009_aav-synapsin-gfp-aav-serotype-1_SL100808.png?v=1770796174"},{"product_id":"scaav-synapsin-gfp-aav-serotype-1-self-complementary-bhv21500010","title":"scAAV-Synapsin-GFP (AAV Serotype 1, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-Synapsin-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500010\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165505389,"sku":"SL100808-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165538157,"sku":"SL100808-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500010_scaav-synapsin-gfp-aav-serotype-1-self-complementary_SL100808-SC.png?v=1770796175"},{"product_id":"aav-mrfp-aav-serotype-1-bhv21500011","title":"AAV-mRFP (AAV Serotype 1)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/1 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-mRFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad CNS and muscle tropism\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500011\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/1 has broad CNS and muscle tropism\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003emRFP is the encoded payload for this construct. A \u003cstrong\u003emRFP + RFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/1 has broad CNS and muscle tropism and is widely used for both in vivo and ex vivo applications.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/1 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mRFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165570925,"sku":"SL100809-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/1 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165603693,"sku":"SL100809-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500011_aav-mrfp-aav-serotype-1_SL100809.png?v=1770796175"},{"product_id":"aav-null-aav-serotype-2-bhv21500012","title":"AAV-Null (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Null\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500012\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eThe null (empty) transgene contains no functional payload, making this vector ideal as a matched delivery and promoter control.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165636461,"sku":"SL100811-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165669229,"sku":"SL100811-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500012_aav-null-aav-serotype-2_SL100811.jpg?v=1770796175"},{"product_id":"aav-gfp-aav-serotype-2-bhv21500013","title":"AAV-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500013\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165701997,"sku":"SL100812-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165734765,"sku":"SL100812-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500013_aav-gfp-aav-serotype-2_SL100812.png?v=1770796176"},{"product_id":"scaav-gfp-aav-serotype-2-self-complementary-bhv21500014","title":"scAAV-GFP (AAV Serotype 2, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500014\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165767533,"sku":"SL100812-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165800301,"sku":"SL100812-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500014_scaav-gfp-aav-serotype-2-self-complementary_SL100812-SC.png?v=1770796176"},{"product_id":"aav-cre-aav-serotype-2-bhv21500015","title":"AAV-Cre (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500015\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165833069,"sku":"SL100813-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165865837,"sku":"SL100813-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500015_aav-cre-aav-serotype-2_SL100813.png?v=1770796176"},{"product_id":"scaav-cre-aav-serotype-2-self-complementary-bhv21500016","title":"scAAV-Cre (AAV Serotype 2, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500016\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165898605,"sku":"SL100813-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165931373,"sku":"SL100813-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500016_scaav-cre-aav-serotype-2-self-complementary_SL100813-SC.png?v=1770796176"},{"product_id":"aav-cre-gfp-aav-serotype-2-bhv21500017","title":"AAV-Cre-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500017\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/2).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020165964141,"sku":"SL100814-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020165996909,"sku":"SL100814-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500017_aav-cre-gfp-aav-serotype-2_SL100814.png?v=1770796177"},{"product_id":"aav-u6-shrna-scramble-gfp-aav-serotype-2-bhv21500018","title":"AAV-U6-shRNA(scramble)-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(scramble)-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500018\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166029677,"sku":"SL100815-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166062445,"sku":"SL100815-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500018_aav-u6-shrna-scramble-gfp-aav-serotype-2_SL100815.png?v=1770796177"},{"product_id":"aav-cag-gfp-aav-serotype-2-bhv21500019","title":"AAV-CAG-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500019\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166095213,"sku":"SL100816-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166127981,"sku":"SL100816-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500019_aav-cag-gfp-aav-serotype-2_SL100816.png?v=1770796178"},{"product_id":"aav-synapsin-gfp-aav-serotype-2-bhv21500020","title":"AAV-Synapsin-GFP (AAV Serotype 2)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500020\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166160749,"sku":"SL100817-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166193517,"sku":"SL100817-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500020_aav-synapsin-gfp-aav-serotype-2_SL100817.png?v=1770796178"},{"product_id":"scaav-synapsin-gfp-aav-serotype-2-self-complementary-bhv21500021","title":"scAAV-Synapsin-GFP (AAV Serotype 2, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/2 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-Synapsin-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Moderate neuronal tropism; canonical benchmark serotype\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500021\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/2 has moderate neuronal tropism; canonical benchmark serotype\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/2 is the canonical AAV serotype with moderate neuronal tropism and is commonly used as a benchmark serotype.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/2 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166226285,"sku":"SL100817-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/2 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166259053,"sku":"SL100817-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500021_scaav-synapsin-gfp-aav-serotype-2-self-complementary_SL100817-SC.png?v=1770796178"},{"product_id":"aav-null-aav-serotype-5-bhv21500022","title":"AAV-Null (AAV Serotype 5)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Null\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500022\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eThe null (empty) transgene contains no functional payload, making this vector ideal as a matched delivery and promoter control.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/5 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166291821,"sku":"SL100818-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166324589,"sku":"SL100818-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500022_aav-null-aav-serotype-5_SL100818.jpg?v=1770796179"},{"product_id":"aav-gfp-aav-serotype-5-bhv21500023","title":"AAV-GFP (AAV Serotype 5)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500023\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/5 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166357357,"sku":"SL100819-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166390125,"sku":"SL100819-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500023_aav-gfp-aav-serotype-5_SL100819.png?v=1770796179"},{"product_id":"scaav-gfp-aav-serotype-5-self-complementary-bhv21500024","title":"scAAV-GFP (AAV Serotype 5, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500024\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/5 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166422893,"sku":"SL100819-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166455661,"sku":"SL100819-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500024_scaav-gfp-aav-serotype-5-self-complementary_SL100819-SC.png?v=1770796179"},{"product_id":"aav-cre-aav-serotype-5-bhv21500025","title":"AAV-Cre (AAV Serotype 5)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500025\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/5).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166488429,"sku":"SL100820-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166521197,"sku":"SL100820-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500025_aav-cre-aav-serotype-5_SL100820.png?v=1770796180"},{"product_id":"scaav-cre-aav-serotype-5-self-complementary-bhv21500026","title":"scAAV-Cre (AAV Serotype 5, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500026\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/5).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166553965,"sku":"SL100820-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166586733,"sku":"SL100820-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500026_scaav-cre-aav-serotype-5-self-complementary_SL100820-SC.png?v=1770796180"},{"product_id":"aav-cre-gfp-aav-serotype-5-bhv21500027","title":"AAV-Cre-GFP (AAV Serotype 5)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500027\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/5).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166619501,"sku":"SL100821-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166652269,"sku":"SL100821-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500027_aav-cre-gfp-aav-serotype-5_SL100821.png?v=1770796180"},{"product_id":"aav-u6-shrna-scramble-gfp-aav-serotype-5-bhv21500028","title":"AAV-U6-shRNA(scramble)-GFP (AAV Serotype 5)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(scramble)-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500028\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166685037,"sku":"SL100822-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166717805,"sku":"SL100822-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500028_aav-u6-shrna-scramble-gfp-aav-serotype-5_SL100822.png?v=1770796181"},{"product_id":"aav-cag-gfp-aav-serotype-5-bhv21500029","title":"AAV-CAG-GFP (AAV Serotype 5)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500029\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/5 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166750573,"sku":"SL100823-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166783341,"sku":"SL100823-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500029_aav-cag-gfp-aav-serotype-5_SL100823.png?v=1770796181"},{"product_id":"aav-synapsin-gfp-aav-serotype-5-bhv21500030","title":"AAV-Synapsin-GFP (AAV Serotype 5)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500030\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/5 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166816109,"sku":"SL100824-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166848877,"sku":"SL100824-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500030_aav-synapsin-gfp-aav-serotype-5_SL100824.png?v=1770796181"},{"product_id":"scaav-synapsin-gfp-aav-serotype-5-self-complementary-bhv21500031","title":"scAAV-Synapsin-GFP (AAV Serotype 5, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/5 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-Synapsin-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Broad, efficient CNS transduction across large volumes\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500031\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/5 has broad, efficient CNS transduction across large volumes\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/5 is one of the most efficient serotypes for broad CNS transduction and is favored for large-scale in vivo experiments.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/5 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166881645,"sku":"SL100824-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/5 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166914413,"sku":"SL100824-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500031_scaav-synapsin-gfp-aav-serotype-5-self-complementary_SL100824-SC.png?v=1770796182"},{"product_id":"aav-null-aav-serotype-6-bhv21500032","title":"AAV-Null (AAV Serotype 6)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Null\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500032\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eThe null (empty) transgene contains no functional payload, making this vector ideal as a matched delivery and promoter control.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/6 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020166947181,"sku":"SL100825-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020166979949,"sku":"SL100825-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500032_aav-null-aav-serotype-6_SL100825.jpg?v=1770796182"},{"product_id":"aav-gfp-aav-serotype-6-bhv21500033","title":"AAV-GFP (AAV Serotype 6)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500033\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/6 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167012717,"sku":"SL100826-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167045485,"sku":"SL100826-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500033_aav-gfp-aav-serotype-6_SL100826.png?v=1770796182"},{"product_id":"scaav-gfp-aav-serotype-6-self-complementary-bhv21500034","title":"scAAV-GFP (AAV Serotype 6, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500034\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/6 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167078253,"sku":"SL100826-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167111021,"sku":"SL100826-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500034_scaav-gfp-aav-serotype-6-self-complementary_SL100826-SC.png?v=1770796183"},{"product_id":"aav-cre-aav-serotype-6-bhv21500035","title":"AAV-Cre (AAV Serotype 6)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500035\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/6).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167143789,"sku":"SL100827-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167176557,"sku":"SL100827-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500035_aav-cre-aav-serotype-6_SL100827.png?v=1770796183"},{"product_id":"scaav-cre-aav-serotype-6-self-complementary-bhv21500036","title":"scAAV-Cre (AAV Serotype 6, Self-complementary )","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500036\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/6).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167209325,"sku":"SL100827-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167242093,"sku":"SL100827-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500036_scaav-cre-aav-serotype-6-self-complementary_SL100827-SC.png?v=1770796183"},{"product_id":"aav-cre-gfp-aav-serotype-6-bhv21500037","title":"AAV-Cre-GFP (AAV Serotype 6)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500037\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/6).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167274861,"sku":"SL100828-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167307629,"sku":"SL100828-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500037_aav-cre-gfp-aav-serotype-6_SL100828.png?v=1770796184"},{"product_id":"aav-u6-shrna-scramble-gfp-aav-serotype-6-bhv21500038","title":"AAV-U6-shRNA(Scramble)-GFP (AAV Serotype 6)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(Scramble)-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500038\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167340397,"sku":"SL100829-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167373165,"sku":"SL100829-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500038_aav-u6-shrna-scramble-gfp-aav-serotype-6_SL100829.png?v=1770796184"},{"product_id":"aav-cag-gfp-aav-serotype-6-bhv21500039","title":"AAV-CAG-GFP (AAV Serotype 6)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500039\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/6 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167438701,"sku":"SL100830-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167471469,"sku":"SL100830-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500039_aav-cag-gfp-aav-serotype-6_SL100830.png?v=1770796185"},{"product_id":"aav-synapsin-gfp-aav-serotype-6-bhv21500040","title":"AAV-Synapsin-GFP (AAV Serotype 6)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500040\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/6 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167569773,"sku":"SL100831-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167602541,"sku":"SL100831-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500040_aav-synapsin-gfp-aav-serotype-6_SL100831.png?v=1770796185"},{"product_id":"scaav-synapsin-gfp-aav-serotype-6-self-complementary-bhv21500041","title":"scAAV-Synapsin-GFP (AAV Serotype 6, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/6 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-Synapsin-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500041\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/6 has strong affinity for skeletal muscle, cardiac muscle, and airway epithelium\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/6 has strong affinity for skeletal and cardiac muscle, as well as airway epithelium.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/6 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167635309,"sku":"SL100831-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/6 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167668077,"sku":"SL100831-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500041_scaav-synapsin-gfp-aav-serotype-6-self-complementary_SL100831-SC.png?v=1770796185"},{"product_id":"aav-null-aav-serotype-8-bhv21500042","title":"AAV-Null (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Null\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500042\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eThe null (empty) transgene contains no functional payload, making this vector ideal as a matched delivery and promoter control.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167700845,"sku":"SL100832-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167733613,"sku":"SL100832-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500042_aav-null-aav-serotype-8_SL100832.jpg?v=1770796185"},{"product_id":"aav-gfp-aav-serotype-8-bhv21500043","title":"AAV-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500043\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167766381,"sku":"SL100833-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167799149,"sku":"SL100833-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500043_aav-gfp-aav-serotype-8_SL100833.png?v=1770796186"},{"product_id":"scaav-gfp-aav-serotype-8-self-complementary-bhv21500044","title":"scAAV-GFP (AAV Serotype 8, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500044\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167831917,"sku":"SL100833-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167864685,"sku":"SL100833-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500044_scaav-gfp-aav-serotype-8-self-complementary_SL100833-SC.png?v=1770796186"},{"product_id":"aav-cre-aav-serotype-8-bhv21500045","title":"AAV-Cre (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500045\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167897453,"sku":"SL100834-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167930221,"sku":"SL100834-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500045_aav-cre-aav-serotype-8_SL100834.png?v=1770796186"},{"product_id":"scaav-cre-aav-serotype-8-self-complementary-bhv21500046","title":"scAAV-Cre (AAV Serotype 8, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500046\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020167962989,"sku":"SL100834-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020167995757,"sku":"SL100834-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500046_scaav-cre-aav-serotype-8-self-complementary_SL100834-SC.png?v=1770796187"},{"product_id":"aav-cre-gfp-aav-serotype-8-bhv21500047","title":"AAV-Cre-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500047\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/8).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168028525,"sku":"SL100835-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168061293,"sku":"SL100835-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500047_aav-cre-gfp-aav-serotype-8_SL100835.png?v=1770796187"},{"product_id":"aav-u6-shrna-scramble-gfp-aav-serotype-8-bhv21500048","title":"AAV-U6-shRNA(scramble)-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(scramble)-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500048\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168094061,"sku":"SL100836-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168126829,"sku":"SL100836-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500048_aav-u6-shrna-scramble-gfp-aav-serotype-8_SL100836.png?v=1770796187"},{"product_id":"aav-cag-gfp-aav-serotype-8-bhv21500049","title":"AAV-CAG-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500049\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168159597,"sku":"SL100837-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168192365,"sku":"SL100837-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500049_aav-cag-gfp-aav-serotype-8_SL100837.png?v=1770796188"},{"product_id":"aav-synapsin-gfp-aav-serotype-8-bhv21500050","title":"AAV-Synapsin-GFP (AAV Serotype 8)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/8 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Efficient liver transduction with broader CNS access than AAV2\/2\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500050\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/8 has efficient liver transduction with broader CNS access than AAV2\/2\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/8 provides efficient liver transduction and broader CNS access compared to AAV2\/2, making it popular in gene therapy research.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/8 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168225133,"sku":"SL100838-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/8 \/ 1x10\u003csup\u003e13\u003c\/sup\u003e VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168257901,"sku":"SL100838-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500050_aav-synapsin-gfp-aav-serotype-8_SL100838.png?v=1770796188"}],"url":"https:\/\/www.ebiohippo.com\/collections\/adeno-associated-viruses-aavs.oembed","provider":"BioHippo","version":"1.0","type":"link"}